Cell MedX Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMXC research report →
Companywww.cellmedx.com
Cell MedX Corp. , a biotech company, focuses on the discovery, development, and commercialization of therapeutic and non-therapeutic products for patients with diabetes, Parkinson's disease, high blood pressure, neuropathy, and kidney functions. It develops and manufactures eBalance Pro System for professional use by healthcare practitioners in a clinical setting; and eBalance Home System for home use for general wellness and pain management treatment, which are controlled by the eBalance Console that acts as the central controller for three pre-programmed microcurrent algorithms, including wellness, pain management, and dual.
- CEO
- David M. Jeffs
- IPO
- 2013
- HQ
- Carson City, NV, US
Price Chart
Valuation
- Market Cap
- $126.33M
- P/E
- -6.84
- P/S
- 0.00
- P/B
- -3.61
- EV/EBITDA
- -10.99
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 60.42%
- ROIC
- 100.35%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-566,293 · -297.44%
- EPS
- $-0.03 · -782.35%
- Op Income
- $0
- FCF YoY
- 2.95%
Performance & Tape
- 52W High
- $0.42
- 52W Low
- $0.42
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.75
- Avg Volume
- 0
Get TickerSpark's AI analysis on CMXC
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CMXC Coverage
We haven't published any research on CMXC yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMXC Report →